Edesa Biotech Inc has released findings from a study involving its monoclonal antibody candidate, paridiprubart, conducted by the University of Toronto. The study found that paridiprubart inhibited inflammation signaling induced by various respiratory pathogens, including Influenza A, coronavirus, and a common bacterium. The company believes that their drug candidate could offer a safe and effective treatment for ARDS caused by coronaviruses, pandemic influenza, and harmful bacteria. EDSA shares are up 5.49% at $0.85.